Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Renalytix PLC

RENX.L ✓ COMPLIANTFree checks used up today ☆ Track — members

LSE · Healthcare · Advanced Medical Equipment & Technology ·

UK Micro Cap Analyst: N/A

Last Close

$0.07

▼ -3.64%

Market Cap $47.02M · Vol 1.40M

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$47.02M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

14.81

Momentum

Beta

1.68

vs Market

52W High

$0.13

47.76% below

52W Low

$0.02

229.01% above

Volume

1.40M

Avg 1.90M

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

81.69%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Renalytix PLC (RENX.L) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does RENX.L pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-11.67%

-1.85%

+85.96%

+171.79%

YTD

-10.17%

-41.11%

-87.98%

-99.30%

Financials & Valuation

TTM · Annual

Total Revenue	$3.00M
Net Income	$-20,400,000.00
Revenue Growth (YoY)	+27.90%
Gross Margin	40.00%
Operating Margin	-566.67%
Net Profit Margin	-680.00%
ROE	N/A
ROA · ROIC	-330.40% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	9.11
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	670.46M

Technical Indicators

50-Day SMA	$0.07
200-Day SMA	$0.05
RSI (14)	14.81
Beta	1.68
52-Week High	$0.13
52-Week Low	$0.02

Volume Today	1.40M
Avg Daily Volume (30D)	1.90M
Relative Volume	0.74x
Volatility (10D)	28.77
Volatility (30D)	90.75
Free Float	81.69%

Analyst Consensus

N/A

Current Price $0.07

Mean Target N/A

52W Low$0.02 52W High$0.13

Current

Target

$0.02 $0.13

Current Analyst target

· 0 analysts

Identifiers

ExchangeLSE

FIGIBBG00VPNC5Z0

ISINGB00BYWL4Y04

CountryUK

Sub-IndustryMedical Diagnostic & Testing Equipment

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

SRT.DE Sartorius AG +4.55% BIOT.ST Biotage AB +0.14% EUZ.DE Eckert & Ziegler SE +1.64% VREX Varex Imaging Corporation -0.05% CEVI.ST CellaVision AB -2.06%

Company Profile

Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. KidneyIntelX, is a vitro diagnostic platform, employs a proprietary algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record or EHR, systems, to generate a patient risk score. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.